Clinical trial of rexlemestrocel-L (MPC-150-IM mesenchymal stem cells) in patients with NYHA class IV heart failure
Phase of Trial: Phase III
Latest Information Update: 14 Jun 2016
Price : $35 *
At a glance
- Drugs Rexlemestrocel-L (Primary)
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- 14 Jun 2016 According to a MESOBLAST media release, results from this trial are expected in the second half of 2017 and will be used to support marketing approval application for rexlemestrocel-L
- 14 Jun 2016 According to a MESOBLAST media release, this trial is close to 60% recruited.
- 25 Nov 2014 The National Institutes of Health has agreed to fund this trial, according to a Mesoblast media release.